Novavax Inc. buy melinda
Start price
31.03.19
/
50%
€10.05
Target price
16.02.20
€18.04
Performance (%)
-28.84%
End price
16.02.20
€7.15
Summary
This prediction ended on 16.02.20 with a price of €7.15. The price of Novavax Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -28.84%. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Novavax Inc. | 4.148% | 4.148% | 78.423% | -91.911% |
iShares Core DAX® | -1.114% | 3.430% | 25.966% | 25.039% |
iShares Nasdaq 100 | 1.816% | 6.911% | 30.390% | 48.139% |
iShares Nikkei 225® | 2.113% | 5.501% | 23.404% | 11.979% |
iShares S&P 500 | 2.038% | 5.327% | 30.881% | 46.982% |
According to melinda what are the pros and cons of Novavax Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Novavax Inc. diskutieren
Secteur Recherche biotechnologique et médicale Agenda 07/05 Présentation
Novavax, Inc. est une société de vaccins au stade clinique qui se consacre à la découverte, au développement et à la commercialisation de vaccins et d'adjuvants à nanoparticules recombinantes. La Société exerce ses activités dans le secteur des vaccins recombinants. Grâce à sa technologie de recombinaison de nanoparticules recombinantes, la Société produit des vaccins candidats pour répondre à la fois aux maladies connues et aux nouvelles maladies émergentes. Le portefeuille de produits de la Société se concentre sur une gamme de maladies infectieuses avec des vaccins candidats en développement clinique pour le virus respiratoire syncytial (VRS), la grippe saisonnière, la grippe pandémique et le virus Ebola (EBOV). Le principal adjuvant de la Société pour les applications humaines, Matrix-M, fait actuellement l'objet d'un essai clinique de phase I/II pour le vaccin candidat contre la grippe pandémique H7N9. Elle teste également Matrix-M conjointement avec son candidat vaccin EBOV dans le cadre d'un essai clinique de phase I. Elle développe actuellement d'autres programmes précliniques dans une série de maladies infectieuses, dont le syndrome respiratoire du Moyen-Orient (SREM).
Nombre d'employés
: 347 personnes.
In the thread Trading Novavax Inc.
Buy beendet
Stopped prediction by melinda for Novavax Inc.
Novavax Inc.
Start price
Target price
Perf. (%)
€14.19
26.05.24
26.05.24
-
26.05.25
26.05.25
19.87%
08.06.24
08.06.24
Could be worthwhile Investment >10% per year
Novavax Inc.
Start price
Target price
Perf. (%)
€9.43
09.05.23
09.05.23
€12.00
09.05.24
09.05.24
-54.40%
10.05.24
10.05.24
Could be worthwhile Investment >10% per year
Novavax Inc.
Start price
Target price
Perf. (%)
€41.50
05.06.22
05.06.22
€50.00
05.06.23
05.06.23
-77.28%
09.05.23
09.05.23
Could be worthwhile Investment >10% per year
Novavax Inc.
Start price
Target price
Perf. (%)
€114.10
07.01.22
07.01.22
€130.00
07.01.23
07.01.23
-63.63%
05.06.22
05.06.22
Could be worthwhile Investment >10% per year
Novavax Inc.
Start price
Target price
Perf. (%)
€147.98
05.12.21
05.12.21
-
05.12.22
05.12.22
-23.17%
07.01.22
07.01.22
Could be worthwhile Investment >10% per year
Novavax Inc.
Start price
Target price
Perf. (%)
€35.54
12.05.20
12.05.20
€205.00
04.11.21
04.11.21
369.84%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Novavax Inc.
Start price
Target price
Perf. (%)
€12.40
19.04.20
19.04.20
-
19.04.20
19.04.20
-
19.04.20
19.04.20
Could be worthwhile Investment >10% per year
Novavax Inc.
Start price
Target price
Perf. (%)
€12.40
19.04.20
19.04.20
-
19.04.20
19.04.20
-
19.04.20
19.04.20
Could be worthwhile Investment >10% per year
Novavax Inc.
Start price
Target price
Perf. (%)
€12.40
19.04.20
19.04.20
-
19.04.20
19.04.20
-
19.04.20
19.04.20
Could be worthwhile Investment >10% per year
Novavax Inc.
Start price
Target price
Perf. (%)
€12.40
19.04.20
19.04.20
-
19.04.20
19.04.20
-
19.04.20
19.04.20
Could be worthwhile Investment >10% per year
Novavax Inc.
Start price
Target price
Perf. (%)
€12.40
19.04.20
19.04.20
-
19.04.20
19.04.20
-
19.04.20
19.04.20
Could be worthwhile Investment >10% per year
Novavax Inc.
Start price
Target price
Perf. (%)
€12.80
07.03.20
07.03.20
-
19.04.20
19.04.20
42.17%
19.04.20
19.04.20
Could be worthwhile Investment >10% per year
Novavax Inc.
Start price
Target price
Perf. (%)
€12.40
07.03.20
07.03.20
-
07.03.20
07.03.20
-
07.03.20
07.03.20
Could be worthwhile Investment >10% per year
Novavax Inc.
Start price
Target price
Perf. (%)
€12.40
07.03.20
07.03.20
-
07.03.20
07.03.20
-
07.03.20
07.03.20
Could be worthwhile Investment >10% per year
Novavax Inc.
Start price
Target price
Perf. (%)
€7.15
16.02.20
16.02.20
-
07.03.20
07.03.20
67.83%
07.03.20
07.03.20
Could be worthwhile Investment >10% per year
Novavax Inc.
Start price
Target price
Perf. (%)
€49.43
01.03.18
01.03.18
€45.10
01.03.18
01.03.18
-7.64%
01.03.18
01.03.18
Could be worthwhile Investment >10% per year
Novavax Inc.
Start price
Target price
Perf. (%)
€21.20
01.08.17
01.08.17
€30.00
14.09.17
14.09.17
8.49%
14.09.17
14.09.17
Could be worthwhile Investment >10% per year
Novavax Inc.
Start price
Target price
Perf. (%)
€19.12
01.08.17
01.08.17
€27.06
14.09.17
14.09.17
8.49%
14.09.17
14.09.17
Could be worthwhile Investment >10% per year
Novavax Inc.
Start price
Target price
Perf. (%)
€38.43
22.09.16
22.09.16
€72.16
23.03.17
23.03.17
-41.78%
23.03.17
23.03.17
Could be worthwhile Investment >10% per year
Novavax Inc.
Start price
Target price
Perf. (%)
€72.34
02.09.14
02.09.14
€100.00
02.03.15
02.03.15
125.21%
02.03.15
02.03.15
Could be worthwhile Investment >10% per year
Novavax Inc.
Start price
Target price
Perf. (%)
€28.98
06.06.13
06.06.13
€40.00
06.12.13
06.12.13
103.17%
06.12.13
06.12.13
Could be worthwhile Investment >10% per year